Clinical Trials

3 studies in Gastroesophageal Reflux Disease

1. Anthropometry in Gastroesophageal Reflux Disease and Esophageal Injury Rochester, MN View Summary
   Close

   Anthropometry in Gastroesophageal Reflux Disease and Esophageal Injury

   Location:

   Rochester, MN

   Trial status:

   Open for Enrollment

   Why is this study being done?

   The investigators will study 100 adult subjects over the age of 18 from the esophageal motility lab who are undergoing clinically indicated 24 hour pH impedance and/or pH studies off acid suppressing medication.. These subjects will not have a prior history of esophageal surgery, or diagnosis of BE. The investigators will obtain consent for taking anthropometric measurements (Waist and hip circumference), and the results of their study. Only those subjects that successfully complete the 24h pH/impedance studies will be included. Subjects will also undergo clinically indicated endoscopy. The investigators will consent these subjects to obtain 4 biopsies (bx) from the gastroesophageal (GE) junction and 4 bx from 5 cm above the GE junction. These bio-specimens will be stored for assessment of tissue injury (PGE2) and tissue immune-histochemistry of BE precursors (CDX1 and CDX2) at a later date.

   NCT ID:

   NCT01570842

   IRB Number:

   11-005468

   • Print Summary
   • View study details
2. Cough Reflex Sensitivity and Bronchial Hyper-responsiveness Jacksonville, FL View Summary
   Close

   Cough Reflex Sensitivity and Bronchial Hyper-responsiveness

   Location:

   Jacksonville, FL

   Trial status:

   Open for Enrollment

   Why is this study being done?

   The aim of this study is to provide pilot data on the possible gastrointestinal predictors of respiratory hyper-responsiveness and how these relate to the clinical sub-types of GERD and visceral acid hypersensitivity.

   NCT ID:

   NCT01777867

   • Print Summary
   • View study details

   Who can I contact for additional information about this study?

   
   
   Jacksonville: Kellie Ruday, BS, RRT 904-953-2255
                       
   

3. CYP2C19 Genotype Predictor of Gastric Acid Suppression Rochester, MN View Summary
   Close

   CYP2C19 Genotype Predictor of Gastric Acid Suppression

   Location:

   Rochester, MN

   Trial status:

   Open for Enrollment

   Why is this study being done?

   Proton pump inhibitors are metabolized through the CYP2C19 hepatic enzyme system. Several variant genotypes of this enzyme exist which may lead to decreased, normal or increased metabolism of the proton pump inhibitor. With alteration of metabolism, the degree of gastric acid suppression achieved and efficacy in treating reflux could be affected. For example, Asian populations who have low activity of CYP2C19, commonly need lower doses of proton pump inhibitors to manage gastroesophageal reflux because of more sustained blood levels and availability of the drug. Theoretically, those patients who are rapid metabolizers would receive less effective treatment with proton pump inhibitors

   NCT ID:

   NCT01824199

   IRB Number:

   12-008053

   • Print Summary
   • View study details

   Who can I contact for additional information about this study?

   Rochester: Debra M. Geno, C.C.R.P. 507-538-0367